Evidence map›Paper›PMID 32848491›Full record

ArticleClinical medicine insights. Arthritis and musculoskeletal disorders2020

The Efficacy and Safety of Highly-Bioavailable Curcumin for Treating Knee Osteoarthritis: A 6-Month Open-Labeled Prospective Study.

Yasuaki Nakagawa, Shogo Mukai, Shigeru Yamada, Satoru Murata, Hiromitsu Yabumoto, Takahiro Maeda, Shota Akamatsu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical medicine insights. Arthritis and musculoskeletal disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Pharmacological Insights and Technological Innovations inPharmaceuticals (Basel, Switzerland) · 2026
    Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yasuaki NakagawaDepartment of Orthopedic Surgery, National Hospital Organization, Kyoto Medical Center, Kyoto, Japan.ORCID https://orcid.org/0000-0002-5664-963X
Shogo MukaiDepartment of Orthopedic Surgery, National Hospital Organization, Kyoto Medical Center, Kyoto, Japan.
Shigeru YamadaDepartment of Orthopedic Surgery, National Hospital Organization, Kyoto Medical Center, Kyoto, Japan.
Satoru MurataDepartment of Orthopedic Surgery, Goshohigashi Clinic, Kyoto, Japan.
Hiromitsu YabumotoDepartment of Orthopedic Surgery, National Hospital Organization, Kyoto Medical Center, Kyoto, Japan.
Takahiro MaedaDepartment of Orthopedic Surgery, National Hospital Organization, Kyoto Medical Center, Kyoto, Japan.
Shota AkamatsuDepartment of Orthopedic Surgery, National Hospital Organization, Kyoto Medical Center, Kyoto, Japan.
Kyoto Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe previously developed a surface-controlled water-dispersible form of curcumin that we called Theracurmin HYPOTHESIS/PURPOSE: We determined the clinical effects of orally administered Theracurmin in patients with knee osteoarthritis over a 6-month period. STUDY

designOpen prospective study.

methodsFifty patients Kellgren-Lawrence grade II, III, or IV knee osteoarthritis who were above 40 years old were enrolled in this clinical study. Theracurmin containing 180 mg/day of curcumin was administered orally every day for 6 months. To monitor for adverse events, blood biochemistry analyses were performed before and after 6 months of each intervention. The patients' knee symptoms were evaluated at 0, 1, 2, 3, 4, 5, and 6 months based on the Japanese Knee Osteoarthritis Measure, the knee pain visual analog scale, and the knee scoring system of the Japanese Orthopedic Association.

resultsFive cases dropped out during the study, but no cases dropped out because of major problems. No major side effects were observed with Theracurmin treatment, including the blood biochemistry analysis results. The effective group included 34 cases (75.6%), while the not-effective group included 11 cases.

conclusionThis study demonstrates the safety and good efficacy of Theracurmin for various types of knee osteoarthritis. Theracurmin shows great potential for the treatment of human knee osteoarthritis.

Indexed as

Curcuminhighly bioavailablehumanknee osteoarthritissafety

Identifiers

PMID32848491
PMCPMC7425263
OpenAlexW3048444808

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.